In patients with solid tumors, including melanoma, elevated TGF-β plasma levels have been demonstrated to correlate with tumor progression, number of metastatic sites, and poor clinical outcome (Junker et al., 1996; Krasagakis et al., 1998; Wikstrom et al., 1998). The gene discussed is TGFB1; the disease is melanoma.